DOP2017000149A - Compuestos de triazolopirimidina y usos de los mismos - Google Patents
Compuestos de triazolopirimidina y usos de los mismosInfo
- Publication number
- DOP2017000149A DOP2017000149A DO2017000149A DO2017000149A DOP2017000149A DO P2017000149 A DOP2017000149 A DO P2017000149A DO 2017000149 A DO2017000149 A DO 2017000149A DO 2017000149 A DO2017000149 A DO 2017000149A DO P2017000149 A DOP2017000149 A DO P2017000149A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- triazolopirimidine
- compounds
- same
- prc2
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se proporciona un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo, el cual se ha mostrado es útil para tratar una enfermedad o trastorno mediado por PRC2 : en donde R1, R2, R3, R4, R5, y n son como se definen en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014094644 | 2014-12-23 | ||
CN2015095320 | 2015-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2017000149A true DOP2017000149A (es) | 2017-07-15 |
Family
ID=55071101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2017000149A DOP2017000149A (es) | 2014-12-23 | 2017-06-21 | Compuestos de triazolopirimidina y usos de los mismos |
Country Status (40)
Country | Link |
---|---|
US (5) | US10220036B2 (es) |
EP (1) | EP3237418B1 (es) |
JP (1) | JP6736559B2 (es) |
KR (1) | KR102534028B1 (es) |
CN (1) | CN107108637B (es) |
AU (1) | AU2015370524B2 (es) |
BR (1) | BR112017010354B8 (es) |
CA (1) | CA2969090C (es) |
CL (1) | CL2017001572A1 (es) |
CO (1) | CO2017005992A2 (es) |
CR (1) | CR20170285A (es) |
CY (1) | CY1121901T1 (es) |
DK (1) | DK3237418T3 (es) |
DO (1) | DOP2017000149A (es) |
EA (1) | EA032416B1 (es) |
EC (1) | ECSP17047153A (es) |
ES (1) | ES2722048T3 (es) |
GT (1) | GT201700146A (es) |
HR (1) | HRP20190805T1 (es) |
HU (1) | HUE043060T2 (es) |
IL (1) | IL252135B (es) |
JO (1) | JO3489B1 (es) |
LT (1) | LT3237418T (es) |
ME (1) | ME03385B (es) |
MX (1) | MX2017008529A (es) |
MY (1) | MY186837A (es) |
NZ (1) | NZ731664A (es) |
PE (1) | PE20171307A1 (es) |
PH (1) | PH12017501016A1 (es) |
PL (1) | PL3237418T3 (es) |
PT (1) | PT3237418T (es) |
RS (1) | RS58679B1 (es) |
SG (1) | SG11201703880VA (es) |
SI (1) | SI3237418T1 (es) |
SV (1) | SV2017005472A (es) |
TN (1) | TN2017000204A1 (es) |
TW (1) | TWI694076B (es) |
UA (1) | UA120945C2 (es) |
UY (1) | UY36462A (es) |
WO (1) | WO2016103155A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6736559B2 (ja) * | 2014-12-23 | 2020-08-05 | ノバルティス アーゲー | トリアゾロピリミジン化合物およびその使用 |
US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
CN109906224B (zh) * | 2016-06-20 | 2022-02-25 | 诺华股份有限公司 | ***吡啶化合物及其应用 |
WO2017221100A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
IL263429B (en) | 2016-06-20 | 2022-08-01 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
CA3030167A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
WO2018136264A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
KR20190111079A (ko) | 2017-01-23 | 2019-10-01 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 이환 화합물 |
WO2018170290A1 (en) * | 2017-03-15 | 2018-09-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fmr1 expression |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
MX2019010354A (es) * | 2017-03-16 | 2019-10-22 | Jiangsu Hengrui Medicine Co | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. |
EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
CN109575013A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
WO2019062435A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
CN109867645B (zh) * | 2017-12-05 | 2021-09-14 | 中国医学科学院药物研究所 | 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法 |
MX2020006273A (es) * | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
CN109942556A (zh) * | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
WO2019145176A1 (en) * | 2018-01-23 | 2019-08-01 | Basf Se | Halogenation of pyridine derivatives |
CN112004816B (zh) | 2018-01-31 | 2024-01-05 | 米拉蒂医疗股份有限公司 | Prc2抑制剂 |
CN110156787B (zh) * | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
CN110734436A (zh) * | 2018-07-19 | 2020-01-31 | 上海青煜医药科技有限公司 | 嘧啶或吡嗪并环化合物及其应用 |
EP3889153A4 (en) * | 2018-11-30 | 2022-09-07 | Tuojie Biotech (Shanghai) Co., Ltd. | PYRIMIDINE AND PENTAGONAL HETEROCYCLE DERIVATIVE OF NITROGEN, METHOD FOR THE PREPARATION AND MEDICAL APPLICATIONS |
CN111518100A (zh) * | 2019-02-02 | 2020-08-11 | 上海青煜医药科技有限公司 | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 |
AU2020241254A1 (en) * | 2019-03-15 | 2021-10-07 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators |
EP3950064A4 (en) * | 2019-04-03 | 2023-01-04 | Tera Stone Co., Ltd | THYMINE NUCLEOBASE BASED TRIAZOLOPYRIMIDINES AND PROCESS FOR THEIR PRODUCTION |
US20220213097A1 (en) * | 2019-04-22 | 2022-07-07 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
US11814734B2 (en) | 2019-05-13 | 2023-11-14 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
KR20220027933A (ko) * | 2019-06-05 | 2022-03-08 | 미라티 테라퓨틱스, 인크. | 암을 치료하기 위한 prc2 억제제로서의 이미다조[1,2-c]피리미딘 유도체 |
EP3980021A4 (en) * | 2019-06-05 | 2023-06-14 | Atnx Spv, Llc | METHODS OF TREATMENT AND/OR PREVENTION OF PSORIASIS |
JP7357146B2 (ja) * | 2019-08-22 | 2023-10-05 | ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド | アザヘテロアリール化合物及びその使用 |
CN114746414A (zh) * | 2019-09-26 | 2022-07-12 | 诺华公司 | 氮杂-喹啉化合物及其用途 |
EP4056570A4 (en) * | 2019-11-01 | 2023-12-20 | ShanghaiTech University | EED INHIBITOR AND PRODUCTION METHOD AND USE THEREOF |
CN113004233B (zh) * | 2019-12-18 | 2022-12-20 | 南京优氟医药科技有限公司 | 一种用于制备prc2抑制剂的化合物、其制备方法和用途 |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种***并嘧啶类化合物及其制备方法和应用 |
WO2021228034A1 (en) * | 2020-05-11 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof |
WO2021240373A1 (en) | 2020-05-28 | 2021-12-02 | Novartis Ag | Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders |
CN114907385A (zh) | 2021-02-10 | 2022-08-16 | 上海青煜医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
WO2023016511A1 (zh) * | 2021-08-11 | 2023-02-16 | 上海青煜医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
CA2346448A1 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
SE519662C2 (sv) * | 2001-07-04 | 2003-03-25 | Asept Int Ab | Ventilanordning vid utportioneringsanordningar |
US6894055B2 (en) * | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
JP4575667B2 (ja) | 2002-03-08 | 2010-11-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬として有用な大環状化合物 |
SI1482932T1 (sl) | 2002-03-13 | 2010-02-26 | Array Biopharma Inc | N3-alkilirani derivati benzimidazola kot inhibitorji mek |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
JP2004238296A (ja) * | 2003-02-04 | 2004-08-26 | Kissei Pharmaceut Co Ltd | 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20060246505A1 (en) | 2003-09-02 | 2006-11-02 | Reinhard Walther | Modulation of the synthesis of insulin |
ATE449168T1 (de) | 2004-06-01 | 2009-12-15 | Univ North Carolina | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
ES2481402T3 (es) | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US7890267B2 (en) | 2006-03-31 | 2011-02-15 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
CA2673784A1 (en) | 2006-12-27 | 2008-07-10 | Usc Stevens-University Of Southern California | Dna methylation markers based on epigenetic stem cell signatures in cancer |
WO2009017670A2 (en) | 2007-07-26 | 2009-02-05 | University Of Massachusetts | Ras-mediated epigenetic silencing effectors and uses thereof |
US8907091B2 (en) | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
WO2010111712A2 (en) | 2009-03-27 | 2010-09-30 | Cold Spring Harbor Laboratory | Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers |
CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
JP5864545B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インドール |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
WO2012151277A1 (en) | 2011-05-02 | 2012-11-08 | Applied Informatic Solutions, Inc. | Kits and methods for selecting a treatment for ovarian cancer |
WO2013010181A2 (en) | 2011-07-14 | 2013-01-17 | University Of Massachusetts | Methods of diagnosing cancer using epigenetic biomarkers |
RU2014117632A (ru) | 2011-09-30 | 2015-11-10 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения злокачественной опухоли |
TR201904660T4 (tr) | 2012-03-12 | 2019-05-21 | Epizyme Inc | İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri. |
WO2014078813A1 (en) | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
WO2014124326A1 (en) | 2013-02-08 | 2014-08-14 | Stem Centrx, Inc. | Novel multispecific constructs |
PL2953941T3 (pl) | 2013-02-11 | 2017-11-30 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania |
EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9776996B2 (en) * | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
US10167286B2 (en) | 2014-02-11 | 2019-01-01 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
KR102486616B1 (ko) | 2014-11-14 | 2023-01-09 | 바스프 에스이 | 질화작용 억제제로서의 벤질프로파르길에테르 |
NO3033944T3 (es) | 2014-12-16 | 2018-07-14 | ||
JP6736559B2 (ja) * | 2014-12-23 | 2020-08-05 | ノバルティス アーゲー | トリアゾロピリミジン化合物およびその使用 |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
MA41272A (fr) | 2014-12-23 | 2017-10-31 | Adama Makhteshim Ltd | 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences |
-
2015
- 2015-12-21 JP JP2017533767A patent/JP6736559B2/ja active Active
- 2015-12-21 PT PT15820637T patent/PT3237418T/pt unknown
- 2015-12-21 CA CA2969090A patent/CA2969090C/en active Active
- 2015-12-21 EP EP15820637.5A patent/EP3237418B1/en active Active
- 2015-12-21 CN CN201580070691.5A patent/CN107108637B/zh active Active
- 2015-12-21 ME MEP-2019-127A patent/ME03385B/me unknown
- 2015-12-21 CR CR20170285A patent/CR20170285A/es unknown
- 2015-12-21 TN TN2017000204A patent/TN2017000204A1/en unknown
- 2015-12-21 WO PCT/IB2015/059843 patent/WO2016103155A1/en active Application Filing
- 2015-12-21 MX MX2017008529A patent/MX2017008529A/es active IP Right Grant
- 2015-12-21 PL PL15820637T patent/PL3237418T3/pl unknown
- 2015-12-21 MY MYPI2017701623A patent/MY186837A/en unknown
- 2015-12-21 AU AU2015370524A patent/AU2015370524B2/en active Active
- 2015-12-21 US US15/538,348 patent/US10220036B2/en active Active
- 2015-12-21 RS RS20190502A patent/RS58679B1/sr unknown
- 2015-12-21 EA EA201791420A patent/EA032416B1/ru not_active IP Right Cessation
- 2015-12-21 LT LTEP15820637.5T patent/LT3237418T/lt unknown
- 2015-12-21 UY UY0001036462A patent/UY36462A/es not_active Application Discontinuation
- 2015-12-21 KR KR1020177016880A patent/KR102534028B1/ko active IP Right Grant
- 2015-12-21 NZ NZ731664A patent/NZ731664A/en unknown
- 2015-12-21 US US14/977,273 patent/US9580437B2/en active Active
- 2015-12-21 BR BR112017010354A patent/BR112017010354B8/pt active IP Right Grant
- 2015-12-21 UA UAA201704770A patent/UA120945C2/uk unknown
- 2015-12-21 HU HUE15820637A patent/HUE043060T2/hu unknown
- 2015-12-21 PE PE2017001154A patent/PE20171307A1/es unknown
- 2015-12-21 ES ES15820637T patent/ES2722048T3/es active Active
- 2015-12-21 DK DK15820637.5T patent/DK3237418T3/da active
- 2015-12-21 SG SG11201703880VA patent/SG11201703880VA/en unknown
- 2015-12-21 SI SI201530725T patent/SI3237418T1/sl unknown
- 2015-12-22 JO JOP/2015/0331A patent/JO3489B1/ar active
- 2015-12-22 TW TW104143216A patent/TWI694076B/zh active
-
2017
- 2017-05-07 IL IL252135A patent/IL252135B/en active IP Right Grant
- 2017-06-01 PH PH12017501016A patent/PH12017501016A1/en unknown
- 2017-06-16 CL CL2017001572A patent/CL2017001572A1/es unknown
- 2017-06-16 CO CONC2017/0005992A patent/CO2017005992A2/es unknown
- 2017-06-21 DO DO2017000149A patent/DOP2017000149A/es unknown
- 2017-06-23 GT GT201700146A patent/GT201700146A/es unknown
- 2017-06-23 SV SV2017005472A patent/SV2017005472A/es unknown
- 2017-07-20 EC ECIEPI201747153A patent/ECSP17047153A/es unknown
-
2019
- 2019-01-11 US US16/246,380 patent/US20190142837A1/en not_active Abandoned
- 2019-04-29 HR HRP20190805TT patent/HRP20190805T1/hr unknown
- 2019-04-30 CY CY20191100456T patent/CY1121901T1/el unknown
-
2020
- 2020-04-30 US US16/863,631 patent/US11207325B2/en active Active
-
2021
- 2021-10-19 US US17/505,271 patent/US11931363B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
CU20160003A7 (es) | Pirazololpiridinaminas sustituidas | |
AR095097A1 (es) | Compuestos de fenoxietoxi | |
ECSP18003372A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
CL2019000487A1 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana. | |
AR098134A1 (es) | Compuestos de urea | |
GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos | |
NZ767083A (en) | Polymorphs of selinexor |